Soliton, Inc. (SOLY) |
| 22.58 0 (0%) 04-24 15:47 |
| Open: | 22.56 |
| High: | 22.59 |
| Low: | 22.56 |
| Volume: | 1,347,169 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 22.6 |
| 52w Low: | 7.53 |
Specializing in medical devices, Soliton, Inc. (SOLY) creates and markets products utilizing its unique rapid acoustic pulse technology platform. Their current offerings include solutions for tattoo removal, with active development underway for treatments targeting cellulite reduction, fibrotic scars, and additional medical applications. The company, established in Houston, Texas, in 2012, has operated as a subsidiary of Allergan plc since December 16, 2021.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Thu, 03 Sep 2026
Soliton Inc (SOLY) Key Financial Ratios – Valuation, Profitability & More - Value Research
Thu, 16 Dec 2021
Allergan Aesthetics Completes Acquisition of Soliton - PR Newswire
Mon, 10 May 2021
Houston medical device co. Soliton to be acquired by Allergan Aesthetics for $550M - The Business Journals
Wed, 05 May 2021
Introducing RESONIC™ - BioSpace
Mon, 01 Feb 2021
Soliton Announces FDA Clearance of Rapid Acoustic Pulse Technology for Use in Cellulite - PR Newswire
Wed, 15 Jul 2020
Soliton Receives FDA Acceptance for 510(k) Application - PR Newswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
